Biosimilars and Generics: Regulatory and Pharmacovigilance Differences

Purpose and Scope

Generic medicines and biosimilars both provide alternatives to previously authorised medicinal products, but the scientific basis on which the two approaches are established is different. A conventional generic is generally developed around a chemically defined active substance and, where applicable, demonstrates pharmaceutical equivalence and bioequivalence to the reference medicinal product. A biosimilar is a biological medicinal product developed through a structured comparability exercise to demonstrate high similarity to a reference biological medicine.

The distinction matters for pharmacovigilance because the two products enter post-authorisation surveillance with different bodies of scientific evidence and different product characteristics. It does not, however, mean that there are two separate pharmacovigilance systems. A biosimilar and a generic are both subject to the applicable EU pharmacovigilance framework. The difference lies principally in the scientific context in which evidence is generated, identified and interpreted.

The comparison is most useful when it separates three questions: how the products are established in relation to their reference medicines; which product characteristics affect interpretation of safety evidence; and which operational controls preserve attribution to the product actually administered.

The term generic is used here for a conventional generic medicinal product within the EU regulatory framework. It does not imply that every non-biological medicine follows an identical development pathway. Similarly, not every biological medicinal product is a biosimilar. The comparison is between the generic and biosimilar regulatory concepts.

The Fundamental Difference Between Equivalence and Similarity

The central distinction begins with the nature of the active substance. Many conventional medicines contain chemically synthesised active substances whose molecular identity can be defined with a high degree of precision. For a generic, the regulatory question can therefore focus on whether the same active substance is present and whether the relevant pharmaceutical and pharmacokinetic characteristics are sufficiently equivalent to those of the reference product.

Biological medicinal products are different. Their active substances are generally produced through biological systems and may contain structural and molecular heterogeneity that is influenced by the expression system, manufacturing process, purification and formulation. The regulatory question for a biosimilar is consequently not whether it is an identical molecular copy of the reference medicine, but whether it is highly similar and whether any differences have clinical significance within the applicable scientific framework.

The table is a conceptual comparison. The evidence required for an individual application depends on the product, pharmaceutical form, route, indication and applicable legislation and guidance.

Why Bioequivalence Can Be Used for Many Generics

For a conventional generic, bioequivalence can provide a bridge between the generic and reference product when systemic exposure is an appropriate surrogate for therapeutic equivalence. Pharmacokinetic parameters such as exposure and peak concentration can be compared using an appropriately designed study and the applicable regulatory criteria.

The approach is not universal in exactly the same form for every generic. Some products require different evidence because systemic exposure does not adequately address the relevant therapeutic question. The important distinction is that bioequivalence is designed to establish a defined relationship between products containing the same chemically defined active substance; it is not a substitute for the broader structural and functional characterisation required for a complex biological product.

Why Biosimilarity Requires a Different Evidence Model

A biological medicinal product can vary across several relevant attributes, including higher-order structure, glycosylation, aggregation, charge variants, purity and biological activity. Some differences may affect function, pharmacokinetics, immunogenicity or other clinically relevant properties. The biosimilar pathway therefore begins with extensive analytical and functional comparison and then addresses residual uncertainty with the evidence most capable of answering the remaining scientific question.

Depending on the product, the development programme can include non-clinical studies, clinical pharmacology, comparative efficacy and safety evidence and immunogenicity assessment. The conclusion is based on the totality of comparative evidence rather than on a single clinical trial or a biological equivalent of a generic bioequivalence test.

The current EMA overarching biosimilar guideline describes the general principles for choosing the reference product and establishing biosimilarity. Rev. 1 remains the current effective version; EMA is consulting on a proposed replacement guideline from 22 July to 31 October 2026. The proposed text is therefore not treated here as the current applicable guideline. [1]

The Role of the Reference Product

Both pathways use a reference medicinal product, but the reference has a particularly central role in biosimilar development. The reference biological medicine provides the benchmark for analytical and functional comparison and contributes an established body of clinical and post-authorisation knowledge.

For a generic, the established characteristics of the reference product support the development programme in combination with evidence establishing the relevant equivalence relationship. For a biosimilar, the reference product remains the comparator across the structured comparability exercise. The applicant seeks to establish high similarity and then resolve residual uncertainty with targeted evidence.

In both cases, reference-product knowledge remains useful after authorisation. It can inform biological plausibility, known risks and comparative assessment. It does not, however, change the identity of the product to which an individual safety report belongs.

Manufacturing and Product Characteristics

Manufacturing is important for every medicinal product, but the relationship between process and product characteristics is particularly prominent for biological medicines. Changes in cell substrate, expression conditions, purification, formulation or other process parameters can affect relevant biological quality attributes.

This does not mean that every manufacturing change creates a safety concern. Regulatory comparability assessment is intended to determine whether the post-change product remains comparable in the relevant respects. Pharmacovigilance can provide complementary post-authorisation evidence if a clinically meaningful safety pattern subsequently emerges.

A biosimilar also has its own manufacturing process and product history. High similarity to the reference product therefore does not eliminate the need for product-specific surveillance.

Immunogenicity

Immunogenicity can be relevant to medicines in general, but it is particularly important for many biological therapeutic proteins. An immune response may alter exposure or biological activity and can sometimes contribute to hypersensitivity or other clinically relevant outcomes.

For a biosimilar, immunogenicity is assessed comparatively with the reference product during development. After authorisation, pharmacovigilance must still evaluate clinically relevant immune-mediated events and interpret antibody findings in their clinical context. Detection of anti-drug antibodies is not itself synonymous with an adverse reaction.

Generic medicines do not normally require the same biological-product immunogenicity framework because their active substances and manufacturing characteristics are fundamentally different. This does not mean that generics are exempt from surveillance of hypersensitivity or other immune-mediated reactions when clinically relevant.

Product Identity and Traceability

Product identity matters for both generic and biosimilar medicines. Several products may contain the same active substance, and product-specific characteristics can become relevant when investigating a safety concern.

For biological medicines, product-level identification can be particularly important because different biological products containing the same active substance or related biological substances can have distinct characteristics. EU GVP guidance therefore gives specific attention to distinguishing biological products for safety surveillance. [2]

A pharmacovigilance system should preserve the identity of the medicinal product actually administered and, where relevant and available, information such as batch or lot, exposure dates and switching history. These controls preserve evidence; they should not be interpreted as evidence that biological medicines are inherently less safe.

Development Evidence and Residual Uncertainty

The different development pathways determine the type of uncertainty that remains when a product enters clinical use. For a conventional generic, the central question is generally whether the alternative product contains the same active substance and meets the applicable requirements for equivalence. For a biosimilar, uncertainty is addressed progressively through analytical and functional comparison followed, where scientifically justified, by targeted non-clinical or clinical evidence. The objective is to establish high similarity and resolve residual uncertainty rather than reproduce the entire development programme of the reference product.

Reference Knowledge and Post-Authorisation Safety

Reference-product knowledge informs pharmacovigilance for both product types. For a generic, knowledge of the active substance and reference product can provide an important basis for understanding expected safety. For a biosimilar, the reference-product safety profile also provides biological and clinical context. A reported event may already be known for the reference product, may be consistent with the expected pharmacology of the biosimilar, or may require product-specific investigation. Reference knowledge informs assessment without determining it in advance.

Reference knowledge is evidence used in assessment; it is not a substitute for identifying the product to which the exposure occurred.

Manufacturing Changes and Comparability

Manufacturing changes occur throughout the lifecycle of medicines. For biological medicines, process conditions can be particularly important because they may influence structural and functional characteristics. Regulatory comparability assessment addresses whether a post-change product remains comparable in the relevant respects. Pharmacovigilance provides complementary post-authorisation evidence if a clinically meaningful safety pattern subsequently emerges. Reports appearing after a manufacturing change do not by themselves establish causality.

This principle applies to reference biological medicines and biosimilars. High similarity to a reference product does not eliminate the need for product-specific surveillance, but neither does every manufacturing change constitute a pharmacovigilance concern.

Immunogenicity

Immunogenicity illustrates why a biological product cannot simply be treated as a generic version of a chemically defined medicine. The immune response to a therapeutic protein can depend on molecular characteristics, aggregation, impurities, formulation, route, treatment duration and patient factors.

For biosimilars, immunogenicity is examined comparatively during development. Post-authorisation surveillance then considers clinically meaningful immune responses in relation to the individual product and clinical circumstances. Anti-drug antibodies may be an important finding, but their significance depends on antibody characteristics and on whether they affect pharmacokinetics, pharmacodynamics, efficacy or safety.

For conventional generics, hypersensitivity and other immune-mediated reactions remain pharmacovigilance concerns when clinically relevant, but comparative immunogenicity of a complex biological protein is not normally the regulatory question.

Product Identity and Traceability

Product identification is important for all medicinal products. Biological-product surveillance can place greater practical emphasis on distinguishing products that share an active substance or have closely related biological characteristics. Relevant information may include product name, active substance, strength and formulation, manufacturer where relevant, batch or lot number, administration date and treatment sequence.

For a biosimilar, distinguishing the product from its reference medicine and from other products containing the same active substance is particularly important. Without that distinction, a signal may be detectable at active-substance level while its product-level distribution remains obscured. The same principle applies to generics: several manufacturers may supply the same active substance, and a product-specific problem can be diluted if reports are analysed only at active-substance level.

Switching and Exposure History

Switching between products can occur with both generic and biological medicines. With biological products, the exposure sequence may be particularly important when a safety event is delayed or potentially immune-mediated. A patient may receive a reference biological, a biosimilar or another biosimilar over time.

An event after a switch does not establish that the newly introduced product caused it. Accurate exposure chronology nevertheless strengthens assessment. Generic substitution can likewise change product exposure, but biosimilar switching adds a biological-product context in which immunogenicity, product characteristics and reference-product knowledge may require additional consideration.

Signal Detection and Comparative Evidence

Signal detection for a biosimilar remains part of the general pharmacovigilance system. Potential signals can arise from spontaneous reports, literature, clinical studies, post-authorisation studies, registries, epidemiological analyses, quality information and other sources.

The biosimilar context adds questions rather than replacing the general process: is the event already known for the reference product; is it biologically plausible for the biosimilar; does the pattern appear product-specific; could switching or reporting behaviour influence the observation; and is quality or manufacturing information relevant?

These questions should not be resolved by automatically pooling all products with the same active substance. Pooling may help evaluate a shared mechanism but can remove the product-level information needed to identify a product-specific pattern.

Comparative evidence can arise from randomised trials, observational studies, registries and post-authorisation studies. A lack of an observed difference does not establish identical incidence for every rare or delayed event, while a numerical difference does not automatically establish a clinically meaningful product difference. Interpretation requires consideration of uncertainty, confounding, exposure and biological plausibility.

Risk Management and Aggregate Evaluation

Risk management for a generic or biosimilar operates within the applicable EU framework. For biosimilars, reference-product knowledge can inform the safety specification and interpretation of new information. The biological-product GVP framework also recognises the relationship between reference products, biosimilars and related biological products when safety information changes. This does not mean that every risk-management action must be identical across products; product-specific differences should be considered where supported by evidence.

Aggregate evaluation integrates evidence over time. For a generic this may include product-specific reports, active-substance experience, literature, epidemiological evidence and reference-product knowledge. For a biosimilar the same broad sources are available, with the additional comparative context of the reference biological and biosimilar development programme.

Safety Communication

Safety communication should identify the relevant product and describe the evidence accurately. Where a concern is relevant to several related products, communication may reflect the shared scientific basis. Where evidence is product-specific, communication should not imply a broader effect without supporting evidence. A statement that a risk is associated with a biological mechanism is not equivalent to a statement that every individual biological product has been shown to carry the same level of risk.

Pharmacovigilance Implementation

The differences established during development become operational only when the pharmacovigilance system preserves enough information to distinguish exposure, product and evidence. A generic and a biosimilar therefore enter the same general pharmacovigilance framework, but the questions asked during assessment may differ because the underlying products and development evidence differ.

Individual Case Processing

Individual case processing begins with the reported clinical event and the available exposure information. For either a generic or a biosimilar, the case should retain the medicinal product that was actually administered rather than replacing it with the reference product or a broader active-substance category.

For a biosimilar, the treatment history may also need to establish whether the patient previously received the reference biological medicine or another biosimilar. This chronology can be relevant to assessment, particularly when an event could be delayed, immune-mediated or related to loss of efficacy. The presence of a previous product does not establish causality for a subsequent product; it provides context for evaluating the case.

Signal Detection and Signal Evaluation

Signal management remains governed by the applicable general pharmacovigilance framework. The distinction between generic and biosimilar products affects the evidence considered during signal evaluation rather than creating a separate signal-management process.

For a generic, assessment may consider product-specific reports, active-substance experience, the reference product, literature, epidemiological evidence and quality information. For a biosimilar, the same sources may be supplemented by the biosimilar development evidence, comparative data, reference-product safety experience and information concerning immunogenicity or switching.

The level at which data are grouped should follow the scientific question. Data may appropriately be considered across products when evaluating a shared pharmacological mechanism or known active-substance risk. Conversely, product-level analysis may be necessary when the hypothesis concerns a manufacturing characteristic, a particular formulation, a batch or another product-specific feature. Pooling should therefore be a methodological decision, not an automatic consequence of shared active substance.

Known Risks and New Information

A known adverse reaction associated with a reference biological medicine may provide important context when the same type of event is reported for a biosimilar. The prior existence of the risk can support biological plausibility and help determine whether further investigation is warranted. It does not, by itself, establish that the biosimilar has the same frequency, severity or clinical profile.

The reverse situation also requires care. An event not previously established for the reference product should not automatically be classified as a biosimilar-specific signal. The assessor should consider the strength and consistency of the evidence, exposure, alternative explanations, biological plausibility and whether the observation is reproducible across sources.

This approach also applies to generics. A product-specific observation should not automatically be attributed to every product containing the same active substance, while a well-established active-substance effect should not be overlooked merely because a particular manufacturer has not previously received reports.

Manufacturing and Quality Information

Pharmacovigilance assessment can intersect with quality and manufacturing investigations when a safety observation suggests a possible relationship with product quality. The interface is particularly relevant for biological medicines because manufacturing processes can influence product characteristics.

A report occurring after a manufacturing change is therefore information that may warrant investigation, but temporal association alone does not demonstrate a causal relationship. Quality information, batch distribution, analytical findings, clinical evidence and other relevant data need to be considered together.

For a biosimilar, the fact that the product was developed through comparison with a reference biological medicine does not eliminate this product-specific assessment. The biosimilar has its own manufacturing process and lifecycle history.

Immunogenicity and Loss of Efficacy

Where immunogenicity is relevant, pharmacovigilance assessment should connect laboratory findings with clinical consequences. The presence of anti-drug antibodies is not, by itself, an adverse reaction or proof of clinically significant loss of efficacy. The characteristics of the immune response and its relationship to exposure, pharmacodynamics, treatment response and clinical events determine its significance.

This consideration is particularly relevant to biosimilars because comparative immunogenicity is part of their development evidence. Post-authorisation surveillance nevertheless remains necessary because rare events, longer exposure and broader patient populations may provide information not available during development.

For conventional generics, the same analytical framework for therapeutic-protein immunogenicity is generally not applicable, but loss of efficacy, hypersensitivity and other clinically relevant reactions remain within the scope of pharmacovigilance when relevant to the product.

Switching and Exposure Reconstruction

A safety report following a switch should preserve the sequence of products and dates whenever the information is available. The purpose is not to assume that switching caused the event, but to establish the exposure history needed to evaluate alternative explanations and potential product-specific patterns.

For biosimilars, exposure reconstruction can involve a reference biological medicine followed by one or more biosimilars, or movement between biosimilars. Such histories can be relevant to the interpretation of delayed events and immune responses. The same principle of chronological exposure reconstruction can be useful for generic substitution, although the biological questions may be different.

A pharmacovigilance database should therefore avoid collapsing multiple related products into a single undifferentiated exposure category when doing so would prevent meaningful assessment of the product actually administered.

Risk Management and Aggregate Evaluation

Risk management uses the applicable pharmacovigilance evidence to identify, characterise and manage important risks. For a biosimilar, established knowledge about the reference product can inform the safety context, while the biosimilar's own clinical and post-authorisation evidence determines whether product-specific action is warranted.

Aggregate evaluation should similarly integrate information from spontaneous reports, literature, studies, registries, epidemiological analyses, quality information and other relevant sources. The relative contribution of each source depends on the safety question and the evidence available.

A mature assessment therefore avoids two symmetrical errors: treating all evidence about the reference product as though it were direct evidence about the biosimilar, and treating the biosimilar as though reference-product knowledge were irrelevant. The appropriate conclusion depends on the question being asked and the strength of the evidence available to answer it.

Safety Communication

Safety information should be communicated at the level supported by evidence. A risk that is established for an active substance or biological mechanism may be relevant to multiple products, whereas a product-specific observation may require communication limited to the affected product or products.

The wording should preserve these distinctions. Describing a concern as a class or active-substance risk should not imply that every product has identical evidence, while describing a product-specific signal should not imply a broader biological effect without supporting evidence.

Governance and Inspection Considerations

The governance objective is to ensure that the distinction between generic and biosimilar products is reflected in the evidence chain without creating unnecessary parallel systems. Procedures, databases, training and oversight should allow staff to identify the administered product, understand the relevant development and regulatory context, and document the reasoning used to integrate comparative evidence.

An inspector evaluating such a system could examine whether product identity is preserved from intake through assessment, whether switching and exposure histories can be reconstructed where relevant, whether product-level and active-substance analyses are used deliberately, and whether reference-product information is distinguished from direct evidence concerning the product under investigation.

Potential failure modes include assigning a biosimilar report to the reference product because the active substance is shared; pooling products before determining whether product-level analysis is necessary; losing batch information during case processing; interpreting temporal association with a manufacturing change as evidence of causality; or using comparative evidence without documenting the scientific question it is intended to answer. These are illustrative failure modes, not statements of specific regulatory inspection findings.

The corrective principle is evidence traceability. The organisation should be able to reconstruct what product was administered, what information was available, what analytical approach was used, what uncertainty remained and why the resulting pharmacovigilance conclusion was reached.

Practical Implementation

A practical system can translate these principles into a small number of linked controls. Case-processing procedures should preserve product identity and relevant exposure chronology. Signal-management procedures should define when active-substance-level, product-level or broader comparative analyses are appropriate. Quality and pharmacovigilance interfaces should permit timely exchange of relevant information without assuming causality. Aggregate evaluations should document how reference-product evidence and biosimilar-specific evidence were weighted.

Training should also address terminology. Staff should understand that a biosimilar is a biological medicinal product, that biosimilarity is a regulatory conclusion based on comparative evidence, and that pharmacovigilance remains product-specific even when related-product knowledge is used to interpret the evidence.

The result is not a more complicated pharmacovigilance system for its own sake. It is a system capable of retaining the distinctions that are necessary to answer the safety question being asked.

Key Takeaways

Generic medicines and biosimilars both provide alternatives to previously authorised medicines, but they are established through different scientific and regulatory pathways. For many conventional generics, the central evidence concerns the same chemically defined active substance and the applicable equivalence relationship, including bioequivalence where appropriate. Biosimilars require a structured comparability exercise because biological active substances have greater structural complexity and process-dependent characteristics.

These differences affect the scientific context of pharmacovigilance, not the fundamental pharmacovigilance system. Both products remain subject to the applicable EU GVP framework. Biosimilar surveillance adds the need to interpret product-specific evidence alongside reference-product knowledge and biological-product characteristics.

The most important practical distinction is between the product exposed and the evidence used to interpret the exposure. A biosimilar case remains a biosimilar case even when the reference product provides important supporting knowledge. Conversely, a finding not previously recognised for the reference product is not automatically a biosimilar-specific signal.

Product identification, exposure history, switching information, appropriate use of comparative evidence, and proportionate integration of quality and manufacturing information are therefore important controls. The same principles apply to generics, although the scientific questions may differ.

Comparative Pharmacovigilance Checklist

Relationship With the Wider Pharmacovigilance Framework

The comparison belongs within the broader biological-product and pharmacovigilance framework. The biological-product framework explains why molecular characteristics, manufacturing, immunogenicity and traceability can influence safety surveillance. The biosimilar framework adds the specific relationship between a biosimilar and its reference biological medicine.

The general pharmacovigilance processes remain the same. Individual case processing establishes exposure-specific evidence; signal management evaluates emerging patterns; aggregate reporting integrates evidence over time; risk management governs identified and potential risks; and benefit-risk evaluation connects safety findings with therapeutic benefit.

The development pathway changes the evidence context entering those processes. It does not predetermine the safety conclusion. A mature system therefore preserves product-level evidence while using comparative and reference-product knowledge where scientifically justified.

References

1. European Medicines Agency. Guideline on similar biological medicinal products (Rev. 1). CHMP/437/04 Rev.1. Current effective version; legal effective date 30 April 2015. EMA is consulting on a proposed replacement guideline from 22 July to 31 October 2026.
2. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): Product- or Population-Specific Considerations II: Biological medicinal products. EMA/168402/2014. Particularly relevant to traceability and the pharmacovigilance of biological products and related products.
3. European Medicines Agency. Biosimilar medicines: Overview. Current EMA overview of biosimilar concepts, development, authorisation and post-authorisation pharmacovigilance.
4. European Parliament and Council. Directive 2001/83/EC on the Community code relating to medicinal products for human use, as amended, including Article 10 and Annex I provisions concerning generic and similar biological medicinal products.
5. European Parliament and Council. Regulation (EC) No 726/2004, as amended, establishing Union procedures for the authorisation and supervision of medicinal products and the pharmacovigilance framework applicable to centrally authorised medicines.
6. European Medicines Agency. Guideline on the investigation of bioequivalence. Applicable scientific guidance for conventional generic medicines, subject to product-specific requirements and exceptions.
7. European Medicines Agency. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMA/CHMP/BMWP/14327/2006 Rev.1.
8. International Council for Harmonisation. ICH Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process.

Regulatory Note

This article distinguishes legal requirements from scientific and regulatory guidance. EU legislation establishes the legal framework for medicinal-product authorisation and pharmacovigilance. EMA guidelines provide scientific and regulatory guidance and should not be presented as legislation.

The current effective overarching EMA biosimilar guideline is Rev. 1. EMA's proposed revision, for which consultation runs from 22 July to 31 October 2026, is not treated as a current applicable requirement. [1]

The comparison of generic and biosimilar pharmacovigilance also contains scientific interpretation and recommended operational practice. Statements about product identification, traceability, exposure reconstruction and evidence integration should not be interpreted as additional legal requirements unless the applicable legislation, regulatory guidance or product-specific documentation establishes them.

Regulatory and scientific guidance can change. Current EU legislation, applicable GVP guidance, effective biosimilar and bioequivalence guidelines, product-specific documentation and relevant national requirements should therefore be checked when applying this framework to a particular product or regulatory decision.